Welcome
Support Centre
05 July 2008 
Current Controlled Trials - Clinical Trials
Trial registration
Unique identification scheme
International databases
home  |   my details  |   ISRCTN Register  |   mRCT  |   UKCTG  |   links  |   information  |   news
Introduction
English introduction Introduction en français Deutsche einleitung
Introducción española Introduzione in italiano
 
Find trials
active registers
UKCTG
mental health register
archived registers
all registers
tips on searching
 
Registration
submit trials
 
Information
about mRCT
mRCT FAQs
data items
memorandum
contributors

DISCLAIMER
The site should not be used to diagnose or treat a health problem. Please consult your doctor.
Terms & conditions

DUPLICATION
Your search result may contain a number of different records for the same trial. This occurs when the same trial is listed in more than one register.

[ ...Back to search results ] [ Print-friendly version ]
A Multicentre, Double-Blind, Randomised, Parallel Group, Placebo-Controlled Trial of LAX-101 (ethyl eicosapentaenoate [EPA]) in Patients with a New or Recurrent Episode of Depression
Source of recordUK Clinical Trials Gateway
ISRCTNISRCTN63565713
Date ISRCTN assigned03/02/2003
Local reference number(s)LA01.01.0008A
Public titleA Multicentre, Double-Blind, Randomised, Parallel Group, Placebo-Controlled Trial of LAX-101 (ethyl eicosapentaenoate [EPA]) in Patients with a New or Recurrent Episode of Depression
Scientific title
AcronymN/A
Disease/condition/study domainDepression
Study hypothesisNot provided at time of registration
Design/methodologyRandomised controlled trial
Research ethics reviewNot provided at time of registration
Countries of trialUnited Kingdom
Participants - inclusion criteria1. Written informed consent
2. Diagnosis of major depressive disorder (Diagnostic and Statistical Manual of Mental Disorders, Fourth edition [DSM-IV])
3. Score of between and including 16 and 25 on the Hamilton Depression Rating Scale (HDRS)
4. No treatment with any antidepressant medication (including St John's Wort) in the last 12 weeks from the date of Visit 0 (screen)
5. Male or female of any race aged 18-75
Participants - exclusion criteriaNot provided at time of registration
Patient information material
Status of trialCompleted
Target number of participantsNot provided at time of registration
InterventionsFour groups randomly allocated to placebo, 0.5 g, 1 g or 2 g/day ethyl EPA on a double blind basis.
Primary outcome measure(s)Not provided at time of registration
Secondary outcome measure(s)Not provided at time of registration
Sources of fundingLaxdale Ltd
Sponsor nameLaxdale Ltd
Sponsor detailsKings Park House
Laurelhill Business Park
Polmaise Road
Stirling
United Kingdom
FK7 9JQ
Sponsor telephone+44 (0)1786 476001
Sponsor fax+44 (0)1786 473137
Sponsor emailadmin@Laxdale.co.uk
Contact nameDr Harald Murck
Contact detailsLaxdale Ltd
Kings Park House
Laurelhill Business Park
Polmaise Road
Stirling
United Kingdom
FK7 9JQ
Contact telephone+44 (0) 1786 476001
Contact fax+44 (0) 1786 473137
Contact emailhmurck@laxdale.co.uk
More informationFor more up-to-date information please go to the ISRCTN link below.
Link to record in ISRCTN RegisterISRCTN63565713
Date last extracted from ISRCTN register17/04/2008
Submit your trial protocol Top studies in medical research Submit to Trials journal
terms & conditions | privacy statement | © Current Controlled Trials Ltd


BioMed Central